Humanized Monoclonal Antibodies to Treat Acinetobacter Infections
Humanized Monoclonal Antibodies to Treat Acinetobacter Infections
批准号:
8591208
负责人:
BRAD J SPELLBERG
金额:
$28.84万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2015-06-30
关键词:
A MouseAcinetobacter InfectionsAcinetobacter baumanniiAcuteAdjuvantAllergic ReactionAntibiotic ResistanceAntibioticsAntibodiesBacteriaBindingCell LineCell surfaceCessation of lifeClinicalClinical ResearchClone CellsCombined Modality TherapyCompetitive BiddingDataDevelopmentDiagnosisDrug resistanceEconomicsEpitope MappingEpitopesEvaluation StudiesExcisionExposure toFailureFc ReceptorFlow CytometryFrequenciesGoalsGram-Negative BacteriaHarvestHumanIgG3ImmuneImmunoglobulin Class SwitchingIn VitroInfectionInflammationLeadMarketingMediatingMembrane ProteinsMethodsMetricMonoclonal AntibodiesMusMutationPathway interactionsPatientsPhasePlacebosPreparationProcessProteinsPublic HealthReactionRecombinantsRegimenResistanceRiskSmall Business Technology Transfer ResearchSurfaceTestingTherapeutic Monoclonal AntibodiesTherapeutic antibodiesToxicologyTranslationsUnited StatesVaccinatedVaccinesVendorbaseclinical toxicologycostexperiencehumanized antibodyhumanized monoclonal antibodiesin vitro testingin vivokillingsmanufacturing processmouse modelnovelnovel therapeuticspathogenpre-clinicalpreventpublic health relevancesuccesstreatment effect
中文摘要
描述(由申请人提供):在过去的十年中,鲍曼不动杆菌已经成为美国和全世界最具抗生素耐药性的病原体之一。这些感染越来越普遍,而且具有高度致命性,造成50-60%的感染者死亡。更糟糕的是,没有已知抗生素可以杀死的鲍曼不动杆菌菌株现在已经出现,并且由于缺乏治疗鲍曼不动杆菌的抗生素,这种菌株的频率将继续增加。鉴于开发治疗鲍曼不整杆菌的新抗生素存在巨大的科学障碍以及抗生素的经济市场失灵,迫切需要针对这种细菌的新治疗方法。我们建议开发一种针对鲍曼不动杆菌的被动疫苗(即一种可用于鲍曼不动杆菌感染患者的抗体)。我们的数据表明,基于抗体的治疗是治疗鲍曼不动杆菌感染的一种有希望的策略。我们首先确定了这种细菌在其表面表达的一种蛋白质,称为OmpA(外膜蛋白a),它似乎是一种合适的疫苗靶点。然后我们发现,将重组OmpA作为活疫苗注射到小鼠体内,然后将接种的小鼠或对照小鼠感染鲍曼不动杆菌,疫苗保护小鼠免受致命的极端耐药(XDR)鲍曼不动杆菌感染。接下来,我们发现疫苗介导的疗效机制是诱导保护性抗体。然后,我们建立了5种不同类型的针对鲍曼不动杆菌OmpA的单克隆抗体(mab)。这些单抗增强了体外对鲍曼不动杆菌的自噬细胞杀伤,并有效地保护了XDR鲍曼不动杆菌致死性感染的小鼠。虽然这些单克隆抗体是一种很有希望的治疗XDR鲍曼杆菌感染的新疗法,但进一步临床开发的可行性将取决于抗体的成功人源化。小鼠单克隆抗体不能用于治疗人类,因为人类对小鼠单克隆抗体产生免疫反应,可能导致单克隆抗体快速清除(因此疗效较低)、全身炎症、严重过敏反应,甚至有死亡风险。人性化的过程可以防止这些不良影响。因此,我们建议将单克隆抗体人源化,同时保留其抗a抗体。鲍曼原虫活性(经体外和体内验证)在两个目标中:1)人源化3个主要候选单克隆抗体,类转换为人IgG3;2)根据体外表面结合和细菌杀伤以及鲍曼不动杆菌感染小鼠模型的体内功效,确定最有效的人源单抗方案。鲍曼不动杆菌感染对公共卫生构成严重威胁,迫切需要开发新的治疗方法,但在未来十年可能没有新的抗生素来治疗这些感染。单克隆抗体有望治疗鲍曼不动杆菌感染。我们提出保守的里程碑(可行性标准),这是我们独特的单克隆抗体作为这种感染的新治疗方法的标准,有系统的开发途径的一部分。进展到II期取决于单克隆抗体的人源化而不丧失疗效。
英文摘要
DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highly lethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue to increase in frequency given the lack of antibiotics in development to treat A. baumannii. Given the tremendous scientific barriers to developing new antibiotics to treat A. baumannii and the economic market failure of antibiotics, new treatments are critically needed for this bacteria. We propose to develop a passive vaccine targeting A. baumannii (i.e., an antibody that can be administered to patients with A. baumannii infection). Our data indicate that antibody-based therapy is a promising strategy to treat A. baumannii infections. We first identified a protein that the bacteria expresses on its surface called OmpA (Outer membrane protein A) that appeared to be a suitable target for a vaccine. We then found that when recombinant OmpA was injected into mice as an active vaccine, and subsequently the vaccinated or control mice were infected with A. baumannii, the vaccine protected mice from otherwise lethal extreme drug resistant (XDR) A. baumannii infection. Next, we discovered that the mechanism of vaccine- mediated efficacy was induction of protective antibodies. We then raised 5 distinct types of monoclonal antibodies (MAbs) against OmpA isolated from A. baumannii. These MAbs enhance opsonophagocytic killing of A. baumannii in vitro and effectively protected mice given a lethal infection with XDR A. baumannii. While these MAbs are a promising new therapy for XDR A. baumannii infections, the feasibility of further clinical development will hinge upon successful humanization of the antibodies. Mouse MAbs cannot be used to treat humans, because humans mount an immune reaction to mouse MAbs that can cause rapid removal of the MAbs (hence lower efficacy), systemic inflammation, severe allergic reactions, and even a risk for death. The humanization process prevents these undesirable effects. We therefore propose to humanize the MAbs while retaining their anti-A. baumannii activity (as verified both in vitro and in vivo) in two AIMS: 1) Humanize 3 lead candidate MAbs, with class switching to human IgG3; 2) Define an optimally effective humanized MAb regimen based on in vitro surface binding and bacterial killing, and in vivo efficacy in a mouse model of A. baumannii infection. A. baumannii infections pose a grave public health threat that urgently demands development of new treatments, but no new antibiotics to treat these infections will likely be available in the coming decade. MAbs hold great promise to treat A. baumannii infections. We propose conservative milestones (feasibility criteria) that are part of a standard, methodical development pathway for our unique MAbs as a novel treatment for such infections. Progression to Phase II depends on humanization of the MAbs without loss of efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections
-
批准号:9899885
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:BRAD J SPELLBERG
-
依托单位:
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections
-
批准号:10646147
-
项目类别:
-
资助金额:$98.94万
-
财政年份:2020
-
负责人:BRAD J SPELLBERG
-
依托单位:
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections
-
批准号:10378255
-
项目类别:
-
资助金额:$99.51万
-
财政年份:2020
-
负责人:BRAD J SPELLBERG
-
依托单位:
Diabetes and Inflammation During Infection
-
批准号:9223117
-
项目类别:
-
资助金额:$20.63万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
The Surface of Hospitals Intensive Environmental Load Disinfection (SHIELD) Study
-
批准号:10013217
-
项目类别:
-
资助金额:$30.87万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
MAb Passive Vaccination against Acinetobacter baumannii
-
批准号:10518413
-
项目类别:
-
资助金额:$75.09万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
MAb Passive Vaccination against Acinetobacter baumannii
-
批准号:9756135
-
项目类别:
-
资助金额:$70.33万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
MAb Passive Vaccination against Acinetobacter baumannii
-
批准号:9440295
-
项目类别:
-
资助金额:$73.12万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
MAb Passive Vaccination against Acinetobacter baumannii
-
批准号:10228579
-
项目类别:
-
资助金额:$69.42万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
MAb Passive Vaccination against Acinetobacter baumannii
-
批准号:10006348
-
项目类别:
-
资助金额:$69.78万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
MAb Passive Vaccination against Acinetobacter baumannii
-
批准号:10634737
-
项目类别:
-
资助金额:$78.8万
-
财政年份:2017
-
负责人:BRAD J SPELLBERG
-
依托单位:
Transferrin Combination Therapy to Address Antimicrobial Resistance
-
批准号:9029371
-
项目类别:
-
资助金额:$66.43万
-
财政年份:2016
-
负责人:BRAD J SPELLBERG
-
依托单位:
Monoclonal antibody passive vaccination to treat XDR Acinetobacter infections
-
批准号:8896096
-
项目类别:
-
资助金额:$42.82万
-
财政年份:2014
-
负责人:BRAD J SPELLBERG
-
依托单位:
Monoclonal antibody passive vaccination to treat XDR Acinetobacter infections
-
批准号:8822414
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2014
-
负责人:BRAD J SPELLBERG
-
依托单位:
Acinetobacter virulence and host innunopathogenesis
-
批准号:9003590
-
项目类别:
-
资助金额:$23.95万
-
财政年份:2013
-
负责人:BRAD J SPELLBERG
-
依托单位:
Acinetobacter virulence and host immunopathogenesis
-
批准号:8445930
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2013
-
负责人:BRAD J SPELLBERG
-
依托单位:
Antibody Targeting of KPC and NDM1
-
批准号:8444990
-
项目类别:
-
资助金额:$17.49万
-
财政年份:2013
-
负责人:BRAD J SPELLBERG
-
依托单位:
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections
-
批准号:8465792
-
项目类别:
-
资助金额:$33.13万
-
财政年份:2009
-
负责人:BRAD J SPELLBERG
-
依托单位:
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections
-
批准号:7731638
-
项目类别:
-
资助金额:$34.74万
-
财政年份:2009
-
负责人:BRAD J SPELLBERG
-
依托单位:
Innate Effectors of rAls3p-N Anti-Candida Vaccine
-
批准号:7724849
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2009
-
负责人:BRAD J SPELLBERG
-
依托单位:
海外基金